Product profile
CJC-1295 (No Dac)/Ipamorelin Blend
Overview
A synergistic growth hormone-releasing peptide blend researched for its role in pulsatile GH secretion, metabolic signaling, and somatotropic axis modulation.
- Concentration
- 10 mg / 10 mg
- Stock
- In stock
Product details
CJC-1295/Ipamorelin is a research-formulated combination of a growth hormone-releasing hormone (GHRH) analogue and a selective ghrelin receptor agonist. The blend is designed to investigate coordinated stimulation of the somatotropic axis, providing a dual-mechanism model for studying growth hormone pulse dynamics and downstream anabolic signaling.
- Receptor Targets: GHRH receptor (CJC-1295), ghrelin receptor/GHS-R1a (Ipamorelin)
- Key Feature: Dual-mechanism GH secretagogue blend with synergistic somatotropic activity
- Research Focus Areas: Growth hormone axis regulation, metabolic homeostasis, body composition signaling, IGF-1 pathway modulation
- Common Models: Neuroendocrine signaling studies, metabolic dysfunction models, GH deficiency paradigms
- Mechanistic Interests: Pulsatile GH release, IGF-1 upregulation, lipolytic and anabolic pathway crosstalk, hypothalamic-pituitary axis dynamics
It is used in research to explore somatotropic signaling cascades, neuroendocrine regulation, and growth hormone-mediated metabolic processes. All products currently listed on this site are for research purposes only.
All products currently listed on this site are for research purposes only.
